Altimmune, Inc.
ALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001326190
In the last 90 days, Altimmune, Inc. insiders filed 4 open-market purchases and 0 sales; 190 institutions reported holding it in 13F filings for Q3 2026, worth $407.4M in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:18 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $88.1M (214861.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Feb 27, 2025 | Mar 27, 2024 | Feb 28, 2023 | Mar 15, 2022 |
| Revenue | $41.0K | $20.0K | $426.0K | -$68.0K | $4.41M |
| Operating expenses | $94.5M | $103.2M | $96.4M | $87.7M | $101.3M |
| Research and development | $66.4M | $82.2M | $65.8M | $70.5M | $74.5M |
| Selling, general and administrative | $28.1M | $21.0M | $18.1M | $17.1M | $15.4M |
| Operating income | -$94.5M | -$103.2M | -$95.9M | -$87.7M | -$96.9M |
| Interest expense | – | – | $35.0K | $8.00K | $5.66K |
| Income tax | -$681.0K | – | – | -$197.0K | – |
| Net income | -$88.1M | -$95.1M | -$88.4M | -$84.7M | -$97.1M |
| EPS, basic | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| EPS, diluted | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Weighted shares, basic | 88.1M | 71.0M | 53.2M | 46.9M | 41.3M |
| Weighted shares, diluted | 88.1M | 71.0M | 53.2M | 46.9M | 41.3M |
| Margins and growth | |||||
| Operating margin | -230461.0% | -515860.0% | -22518.5% | – | -2197.4% |
| Net margin | -214861.0% | -475295.0% | -20762.2% | – | -2201.4% |
| Revenue growth, year over year | +105.0% | −95.3% | – | −101.5% | −46.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Feb 27, 2025 | Mar 27, 2024 | Feb 28, 2023 | Mar 15, 2022 |
| Cash and equivalents | $43.8M | $36.9M | $135.1M | $111.1M | $190.3M |
| Short-term investments | $229.7M | $95.0M | $62.7M | $73.8M | – |
| Total current assets | $278.2M | $137.3M | $209.6M | $192.8M | $204.1M |
| Property, plant and equipment | $312.0K | $413.0K | $651.0K | $1.08M | $1.45M |
| Intangible assets | – | $0 | $0 | $12.4M | $12.4M |
| Total assets | $279.9M | $139.3M | $210.6M | $206.9M | $218.9M |
| Accounts payable | $2.72M | $211.0K | $2.07M | $4.80M | $2.03M |
| Total current liabilities | $15.0M | $10.5M | $12.1M | $17.1M | $18.3M |
| Long-term debt | $34.3M | – | – | $4.58M | $1.45M |
| Total liabilities | $55.0M | $15.8M | $16.5M | $21.6M | $19.7M |
| Shareholders' equity | $224.9M | $123.5M | $194.1M | $185.3M | $199.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Feb 27, 2025 | Mar 27, 2024 | Feb 28, 2023 | Mar 15, 2022 |
| Operating cash flow | -$67.5M | -$79.8M | -$75.8M | -$62.6M | -$78.2M |
| Capital expenditures | $11.0K | – | $47.0K | $126.0K | $12.1M |
| Free cash flow | -$67.5M | – | -$75.9M | -$62.7M | -$90.4M |
| Depreciation and amortization | – | – | – | -$205.0K | $551.3K |
| Stock-based compensation | $16.1M | $14.4M | $10.6M | $8.10M | $5.52M |
| Investing cash flow | -$132.5M | -$28.4M | $13.7M | -$73.4M | $87.5M |
| Financing cash flow | $206.8M | $10.0M | $86.1M | $56.8M | $65.1M |
| Net change in cash | $6.83M | -$98.2M | $24.0M | -$79.2M | $74.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 39209.8% | 71965.0% | 2497.7% | – | 125.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 194.6M | +86.6% | SEC |
| Aug 7, 2026 | 194.5M | +120.4% | SEC |
| May 8, 2026 | 194.5M | +139.8% | SEC |
| Feb 27, 2026 | 130.1M | +68.9% | SEC |
| Oct 31, 2025 | 104.3M | +46.6% | SEC |
| Aug 8, 2025 | 88.3M | +24.2% | SEC |
| May 9, 2025 | 81.1M | +14.4% | SEC |
| Feb 24, 2025 | 77.0M | +8.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.